Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer

Yamasaki, Masahiro; Murakami, Isao; Nakano, Kikuo; Doi, Mihoko; Kitaguchi, Souichi; Kondo, Tomohiro; Sakurai, J.; Hattori, Noboru; Arita, Ken-ichi

doi:10.21873/anticanres.11400

Cited by 11 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these diagnostic methods provide limited information and are insufficient for an accurate and in depth understanding of the molecular changes taking place during tumor genesis and development (1). Therefore, research into the molecular classification of lung cancer may contribute to more targeted treatments and accurate prognosis (4). The present study revealed that miR-145 expression was downregulated in patients with NSCLC compared with normal healthy volunteers, however there were only a total of six individuals in each group, which is a small sample size and represents a limitation of the study.…”

Section: Discussionmentioning

confidence: 99%

“…The molecular network underlying the development of lung cancer has been partially identified at the protein and gene level. Over the past 10 years, gene therapy based on the underlying molecular network of lung cancer development has advanced, however, the overall 5-year mortality rate for patients with lung cancer has not significantly improved (4).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA‑145 inhibits migration and induces apoptosis in human non‑small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway

Ding

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

In the present study, the therapeutic effects and the underlying molecular mechanisms of microRNA (miR)‑145 were investigated in non‑small cell lung cancer (NSCLC) cells. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to examine miR‑145 expression. An MTT assay and flow cytometry were used to investigate cell proliferation and apoptosis, respectively. The protein expression of Bax, epidermal growth factor receptor (EGFR), phosphatidylinositol 3‑kinase (PI3K) and phosphorylated‑protein kinase B (AKT) was examined by western blot analysis. miR‑145 expression was downregulated in patients with NSCLC who were treated with chemotherapy. The downregulation of miR‑145 in A549 cells reduced lactate dehydrogenase (LDH) expression, apoptosis, caspase‑3/-9 levels and Bax protein expression, while it increased cell proliferation. Upregulation of miR‑145 in A459 cells increased LDH, apoptosis, caspase‑3/-9 levels and Bax protein expression, while it inhibited cell proliferation. The EGFR/PI3K/AKT signaling pathway was suppressed by miR‑145 upregulation in A549 cells and induced by miR‑145 downregulation. The EGFR inhibitor suppressed the EGFR/PI3K/AKT signaling pathway and increased the anticancer effects of miR‑145 upregulation in A549 cells. The PI3K inhibitor suppressed the PI3K/AKT signaling pathway and reversed the anticancer effects of miR‑145 upregulation in A549 cells. In conclusion, the present study demonstrated that miR‑145 regulates the EGFR/PI3K/AKT signaling pathway in patients with NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MicroRNA‑145 inhibits migration and induces apoptosis in human non‑small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway

Ding

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…[70] Bevacizumab is a recombinant, humanised, monoclonal antibody (93% human, 7% murine) that binds all isoforms of circulating VEGF-A, preventing VEGF-A binding to its receptors. Bevacizumab is currently licensed for the treatment of metastatic colorectal cancer, [71] non-small-cell lung carcinoma (NSCLC), [72] glioblastoma multiforme of the brain, [73] metastatic renal cell carcinoma, [74] cervical cancer [75] and ovarian cancer. [76] follow-up.…”

Section: Veg F-a Inhib Iti On a S A Novel S Tr Ategy For The Manag mentioning

confidence: 99%

Vascular endothelial growth factor‐A as a promising therapeutic target for the management of psoriasis

Luengas‐Martinez

Hardman‐Smart

Paus

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

Vascular endothelial growth factor‐A (VEGF‐A), the main angiogenic mediator, plays a critical role in the pathogenesis of several inflammatory immune‐mediated diseases, including psoriasis. Even though anti‐angiogenic therapies, such as VEGF inhibitors, are licensed for the treatment of various cancers and eye disease, VEGF‐targeting interventions are not part of current psoriasis therapy. In this viewpoint essay, we argue that the existing preclinical research evidence on the role of VEGF‐A in the pathogenesis of psoriasis as well as clinical observations in patients who have experienced psoriasis remission during oncological anti‐VEGF‐A therapy strongly suggests to systematically explore angiogenesis targeting also in the management of psoriasis. We also point out that some psoriasis therapies decrease circulating levels of VEGF‐A and normalise the psoriasis‐associated vascular pathology in the papillary dermis of plaques of psoriasis and that a subset of patients with constitutionally high levels of VEGF‐A may benefit most from the anti‐angiogenic therapy we advocate here. Given that novel, well‐targeted personalised medicine therapies for the development of psoriasis need to be developed, we explore the hypothesis that VEGF‐A and signalling through its receptors constitute a promising target for therapeutic intervention in the future management of psoriasis.

show abstract

“…CSP-9 cleaves pro -caspase-3, producing active caspase. Caspases (CSP), like other enzymes, act catalytically, allowing a small number of initiator CSP to activate a large number of effector CSP 53 . The accidental activation of CSP could result in apoptosis, but this is prevented by IAPs 54 .…”

Section: Mtl Dynamics and Cell Cyclementioning

confidence: 99%

Untitled

2021

IJPSR

View full text Add to dashboard Cite

Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer

Abstract: Carboplatin plus weekly paclitaxel with bevacizumab was effective and well tolerated by patients with advanced NSCLC.

Cited by 11 publications

References 13 publications

MicroRNA‑145 inhibits migration and induces apoptosis in human non‑small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway

MicroRNA‑145 inhibits migration and induces apoptosis in human non‑small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway

Vascular endothelial growth factor‐A as a promising therapeutic target for the management of psoriasis

Untitled

Contact Info

Product

Resources

About